Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

Humanized anti-IL-6 antibody shows good efficacy and safety as rheumatoid arthritis Rx

Dec. 28, 1998

Oral human immunoglobulin proves to be safe and effective treatment for RA

Dec. 23, 1998

Design of potent MAP kinase p38 inhibitors reported by R.W. Johnson

Dec. 23, 1998

Patent assigned to Sumitomo describes new compounds for immune and inflammatory disorders

Dec. 23, 1998

Immune Response announces phase IIb trial results for RA

Dec. 23, 1998

New cell adhesion inhibitors in development at Lilly for inflammatory disorders, etc.

Dec. 22, 1998

Another group of MMP inhibitors discovered at Hoechst

Dec. 22, 1998

Compounds for inhibiting matrix metalloproteinases in development at Hoechst Marion Roussel

Dec. 21, 1998

Boehringer Ingelheim submits U.S. NDA for osteoarthritis treatment

Dec. 18, 1998

MMP inhibitors synthesized and evaluated for biological activity at Hoechst Marion Roussel

Dec. 17, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...